Alain H. Rook

faculty photo
Professor of Dermatology
Department: Dermatology

Contact information
Department of Dermatology
3400 Civic Center Boulevard
Perelman Center for Advanced Medicine
Philadelphia, Pa. 19104
Philadelphia, PA 19104
Office: 215-662-7610
Fax: 215-349-8173
B.A. (Biology)
Brandeis University, 1971.
M.D. (Medicine)
University of Michigan, 1975.
Permanent link

Description of Itmat Expertise

Dr. Rook's current research focuses on immunotherapeutic approaches to cutaneous T-cell lymphoma including 1) the development of novel immunomodulatory agents for therapy, 2) the elucidation of mechanisms of action of new therapeutic agents and 3) the mechanisms for the endogenous immunosuppression caused by the malignant T-cells in CTCL

Selected Publications

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC: Clinically significant responses achieved with romidespsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma (20), 1-22, March 2015.

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S.: Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma 20: 1-22, March 2015.

Cedeno-Laurent F, Singer Em, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH.: Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol 158(1): 1-7, March 2015.

Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A.: Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hell J Nucl Med 17(2): 78-84, May-August 2014.

Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH.: CD164 and FCRL3 are highly expressed on the CD4+CD26- T-cells in Sezary Syndrome patients. J Invest Dermatol 134: 229-36, 2014.

Samimi S, Chu E, Seykora J, Loren A, Vittorio C, Rook A, Rosenbach M, Kim EJ.: Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol 149(5), May 2013.

Kim YH, Demierre MF, Kim EJ, Lerner A, Rook AH, Duvic M, Robak T, Samtsov A, McCulloch W, Chen SC, Waksman J, Nichols J, Whittaker S.: Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma 54(2): 284-9, February 2013.

Lessin SR, Duvic M, Guitart J, Pandya AG, STrober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH.: Topical chemotherapy in cutaneous T-cell lymphoma: Positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02% gel, in mycosis fungoides. JAMA Dermatol 149(1): 25-32, January 2013.

Samimi S, Morrissey K, Anshelevich S, Evans K, Gardner J, Musiek A, Vittorio C, Rook A, Kim E.: Romidepsin and interferon gamma: A novel combination for refractory cutaneous T-cell lymphoma. J Am Acad Dermatol 68(1): e5-6, January 2013.

Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA.: TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19: 3755-63, 2013.

back to top
Last updated: 08/24/2017
The Trustees of the University of Pennsylvania